Posters & Abstracts

  • AACR
    • A Four-pronged Imaging Approach to Characterization of Bone Metastasis in Mouse Models.
    • Value of 1H magnetic resonance spectroscopy in predicting response to standard chemotherapy and radiation in intracranial U87-MG-luc glioma.
    • Regional analysis of DCE MR images to unravel tumor growth and response heterogeneity in SW-620 human colon adenocarcinoma xenografts
    • Bioluminescence imaging of radiation induced tumor growth inhibition in orthotopic mouse models.
    22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics"
    • Monitoring radiation therapy in orthotopic mouse models by bioluminescence imaging.
    • Multi-modality in vivo imaging of bone metabolism and tumor growth in a mouse model of bone metastasis.
    World Molecular Imaging Congress
    • Non-invasive in vivo Monitoring of Bone Metastasis in Mouse Models Using CT, [18F]-NaF PET, and Optical Imaging.
  • AACR
    • Characterization of an orally bioavailable homologue of MPC-6827 (MPI-0443803) that maintains high brain penetration and is not a substrate for multidrug resistance pumps.
    • A potent tubulin binding and vascular disrupting agent with high brain penetration and anti-tumor activity in a mouse orthotopic glioma model.
    International Society for Magnetic Resonance in Medicine (ISMRM)
    • Imaging an inflammatory response in a sponge granuloma model using 19F-MRI.
  • AACR
    • Activity of TG01, a selective COX-2 inhibitor, alone and in combination with standard agents in human breast carcinoma xenografts.
    Society for Molecular Imaging (SMI)
    • Fluorine-19 nanoemulsion for imaging macrophages using MRI.
    Inflammation Research Association
    • Imaging an inflammatory response using 19F-MRI Poster.
    • Imaging an inflammatory response using 19F-MRI Presentation.
  • EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics"
    • Synergistic activity of aflibercept (VEGF Trap) in combination with 5-fluorouracil and irinotecan in preclinical tumor models.
  • AACR
    • Accelerated Evaluation of Tumor Treatment Response by Diffusion MRI.
    • Diffusion MRI Early Prediction of Survival using Solvent Facilitated Perfusion of BCNU in a Rat Model of Glioma Perfusion of BCNU in a Rat Model of Glioma.
    • Efficacy of temozolomide in a transgenic model of glioma: MRI determined tumor growth inhibition and diffusion response are predictive of survival.
    • In vivo MRI evaluation of targeted nanoparticles in rat 9L brain tumor.
    • Intratumoral injection of BCNU in ethanol (DTI-015) and BCNU in ethanol/PEG400 cure subcutaneous C26 tumors.
    • Preclinical efficacy prediction using diffusion MRI.
    • Bioluminescence imaging of apoptosis correlates with diffusion MRI detection of cell kill after treatment of subcutaneous D54 xenografts.
    SMI
    • Bioluminescence imaging of apoptosis and diffusion MRI detection of cell kill in preclinical drug development.
    • In vivo anti-cancer efficacy screening using diffusion MRI.
    ISMRM
    • Apparent diffusion coefficient predicts survival in a transgenic model of glioma.
    • Accelerated evaluation of tumor treatment
  • AACR
    • MRI Predicts Tumor Grade and Survival in a tv-a Transgenic Model of Glioma.
    • MRI Determination of Temozolamide Treatment Response in a tv-a Transgenic Model of Glioma.
    • Evaluation of MRI in a Mouse Model of Liver Metastasis.
    • In vivo Micro-CT of Mouse Lungs Without Respiratory Gating.
    • In Vivo Imaging of a Mouse Model of PC-3 Bone Metastasis.
    Society of Nuclear Medicine (SNM)
    • Flex: Tri-Modality Small Animal Tomography Combining PET, SPECT and CT in a Single Modular Gantry.
  • EORTC-NCI-AACR
    • High field MRI characterization of tumor growth kinetics, vascularity and cellularity in a PDGF-driven tv-a mouse model of glioma.
    • Assessment of treatment efficacy in preclinical drug testing using magnetic resonance imaging.
    AACR
    • High throughput MRI in the use and development of preclinical mouse tumor models.
    • High field MRI characterization of tumor growth kinetics, vascularity and cellularity in a PDGF-driven tv-a mouse model of glioma.
    • Diffusion MRI in preclinical drug testing: an early surrogate marker for efficacy in subcutaneous human tumor xenografts.
    • Synthesis and SAR development of PD03259901, a potent and highly bioavailable MEK inhibitor.
    • The Biological Profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential.
    • Highly selective inhibition of Cdk4 with pyridol [2.3-d] pyrimidin-7-ones.
    • Inhibition of Cdk4 causes tumor regression.
    • Characterization of a novel MEK inhibitor (PD181461) which inhibits human hepatocellular carcinoma growth in vitro and in vivo.
    • Gene expression changes link to efficacy in human tumor xenografts treated with the CDK4/6 inhibitor PD0332991.
    • PK/PD modeling of biomarker (p-ERK) response and tumor growth to PD 0325901 in a human tumor xenograft mouse model.
    • Survivin protein expression is markedly reduced in human colon cancer xenografts treated with the CDK4/6 inhibitor PD 3329991.
    ISMRM
    • MRI characterization of tumor development in a tv-a transgenic mouse model of glioma.